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Therapies for hormone-independent prostate and breast cancer are limited, with the effectiveness of the taxanes compromised by
toxicity, lack of oral bioavailability and drug resistance. This study aims to identify and characterise new microtubule disruptors, which
may have improved efficacy relative to the taxanes in hormone-independent cancer. 2-Methoxy-3-O-sulphamoyl-17b-cyanomethyl-
oestra-1,3,5(10)-triene (STX641), 2-methoxy-3-hydroxy-17b-cyanomethyl-oestra-1,3,5(10)-triene (STX640) and 2-methoxyoestra-
diol-3,17-O,O-bis-sulphamate (STX140) were all potent inhibitors of cell proliferation in a panel of prostate and breast cancer cell
lines. STX641 and STX640 significantly inhibited tumour growth in the MDA-MB-231 xenograft model. STX641 inhibited both in vitro
and in vivo angiogenesis. Despite good in vivo activity, STX641 was not as potent in vivo as STX140. Therefore, STX140 was evaluated
in the prostate hormone-independent PC-3 xenograft model. STX140 had superior efficacy to docetaxel, 2-MeOE2 and
bevacizumab. In contrast to vinorelbine, no significant toxicity was observed. Furthermore, STX140 could be dosed daily over a 60-
day period leading to tumour regression and complete responses, which were maintained after the cessation of dosing. This study
demonstrates that STX641 and STX140 have considerable potential for the treatment of hormone-independent breast and prostate
cancer. In contrast to the taxanes, STX140 can be dosed orally, with no toxicity being observed even after prolonged daily dosing.
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Prostate cancers initially respond to androgen ablation therapy;
however, most will progress to hormone-independent disease and
subsequent advanced metastatic cancer. Few efficacious treatment
options are available for advanced prostate cancer, although recent
studies have shown the taxanes to offer modest clinical benefit
(Berry and Eisenberger, 2005). While much progress has been
made in the treatment of ER-positive breast cancer, such as the
recent introduction of aromatase inhibitors, fewer options are
available for hormone-independent breast cancer. The taxanes,
paclitaxel (taxol) and docetaxel (taxotere), are routinely used in
late-stage metastatic breast cancer and have also been successfully
trialled in the adjuvant and neoadjuvant setting for early breast
cancer (Ring and Ellis, 2005). Although initially responsive, many
tumours quickly become resistant to taxane therapy and the
disease progresses. In vivo, this resistance is largely due to the
expression of the P-glycoprotein pump (Fojo and Menefee, 2005)
and/or the overexpression of the b type III tubulin isoform
(Burkhart et al, 2001). In addition, the toxicity of the taxanes limits
their use. Standard therapies with taxanes are based around a
schedule of one dose every 3 weeks, and before i.v. taxane therapy
can be administered the patients need to be premedicated
with dexamethasone to prevent hypersensitivity reactions
(Marchetti et al, 2002; Crown et al, 2004). Thus, there is an unmet
need, in both hormone-independent prostate and breast
cancers, to develop a new series of compounds with the anti-
tumour properties of the taxanes but with an improved clinical
profile.
Targeting tumour angiogenesis is a major focus of anti-cancer
research; however, to date, few single-agent anti-angiogenic agents
have entered clinical use (Eskens, 2004). There has been success in
combining anti-angiogenic agents with conventional chemother-
apy, such as the recent successful trial of bevacizumab with 5-
fluorouracil-based chemotherapy for metastatic colon cancer
(Hurwitz et al, 2004). Furthermore, the potential anti-angiogenic
activity of many conventional chemotherapy agents is being
explored by the use of low-dose metronomic dosing, in an effort to
combine their anti-tumour activity with an anti-angiogenic activity
(Vacca et al, 1999; Hanahan et al, 2000; Bertolini et al, 2003).
However, such dosing regimes, while likely to be anti-angiogenic,
will result in the drug being used at a suboptimal dose for direct
anti-tumour effects. Therefore, development of agents, which
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starget the tumour cells directly, target the tumours blood supply
and can be administered regularly should prove to be a productive
area of research (Eskens, 2004).
One such potential agent is the natural metabolite of oestradiol,
2-methoxyoestradiol (2-MeOE2), which over the last decade has
shown promise both in vitro and in vivo (Pribluda et al, 2000;
Dingli et al, 2002; Lakhani et al, 2003). 2-Methoxyoestradiol is an
anti-angiogenic and anti-proliferative agent in vitro (Zhu and
Conney, 1998; Shang et al, 2001). 2-Methoxyoestradiol inhibits the
in vivo growth of xenografts derived from human MDA-MB-435
breast cancer cells, MethA sarcomas, B16 melanomas and the
multiple myeloma cell line KAS-6/1 in nude mice (Fotsis et al,
1994; Klauber et al, 1997; Dingli et al, 2002). However, the in vivo
efficacy of 2-MeOE2 is poor, with comparatively high oral (p.o.) or
intraperitoneal (i.p.) doses of 75 and 150mgkg
 1 per day,
respectively, being required to reduce the growth of melanoma
or myeloma tumours in rodent models (Klauber et al, 1997; Dingli
et al, 2002). In phase I trials, a clinical benefit was shown only in
two patients who were receiving 1600–3200mgday
 1 2-MeOE2
orally. The trial was stopped early due to extremely low plasma
concentrations of 2-MeOE2 even at 3000mgday
 1 (Dahut et al,
2006). One possible explanation is provided by the observation
that 2-MeOE2 is oxidised in vitro by tumour cell lines, which
express 17b-HSD type 2 (Purohit et al, 2000; Liu et al, 2005).
The gastrointestinal tract expresses 17b-HSD type 2 (Sano et al,
2001), and this may inactivate 2-MeOE2 before it enters the blood
stream. This is supported by data from a recent phase I trial in
which a daily oral dose of 1000mg 2-MeOE2 was given to 24
patients with advanced metastatic breast cancer. Metabolism
studies showed that 80–95% of the 2-MeOE2 was oxidised to
2-methoxyoestrone (2-MeOE1), and furthermore, 80–90% of both
2-MeOE2 and 2-MeOE1 were present as glucuronide or sulphate
conjugates. Additional evidence for the poor oral bioavailability
of 2-MeOE2 comes from the work of Ireson et al (2004), who
demonstrated that 2-MeOE2 could not be detected in the plasma of
rats 1h after administration of a single oral dose of 2-MeOE2
(10mgkg
 1). The problems of poor bioavailability and rapid
metabolism associated with this drug may be overcome by
synthesising analogues resistant to conjugative and metabolic
inactivation (Leese et al, 2005b). One such compound is
2-methoxyoestradiol-3,17-O,O-bis-sulphamate (STX140), whose
potential anti-angiogenic and anti-tumour activities have been
well documented (Day et al, 2003; Ho et al, 2003; Newman et al,
2004; Wood et al, 2004; Raobaikady et al, 2005; Utsumi et al, 2005;
Leese et al, 2006).
In the present study, we characterise the recently developed
(Utsumi et al, 2005) C-17-substituted compound, 2-methoxy-
3-O-sulphamoyl-17b-cyanomethyl-oestra-1,3,5(10)-triene (STX641)
and the corresponding nonsulphamoylated compound, 2-methoxy-
3-hydroxy-17b-cyanomethyl-oestra-1,3,5(10)-triene (STX640). Further-
more, we assess their in vivo efficacy in hormone-independent
cancer and compare them with STX140.
MATERIALS AND METHODS
Drug synthesis
2-Methoxyoestrone (2-MeOE1, Figure 1, compound 1) and
2-methoxyoestradiol (2-MeOE2, Figure 1, compound 2) were
synthesised by literature routes (Leese et al, 2005a). 2-Methoxy-
oestradiol-3,17-O,O-bis-sulphamate (STX140; Figure 1, compound
5) was synthesised by reaction of 2-MeOE2 with sulphamoyl
chloride in dimethylacetamide (DMA) (Leese et al, 2006). The 17-
cyanomethyl compounds 3 and 4 were elaborated from 2-methoxy-
3-O-benzyloestrone by Wadsworth–Emmons reaction followed by
hydrogenolysis to afford 3. Sulphamoylation of compound 3 with
sulphamoyl chloride in DMA yielded the 3-O-sulphamate deriva-
tive compound 4. Full details of these syntheses will be reported
elsewhere.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were obtained
from TCS Cellworks (Claydon, UK) and maintained in large vessel
endothelial medium supplemented with basic fibroblast growth
factor / heparin, epidermal growth factor and cortisol in the
presence of amphoteracin/gentomycin (TCS Cellworks). Human
adult dermal fibroblasts were obtained from TCS Cellworks and
maintained in fibroblast growth medium (TCS Cellworks) with the
same supplements as used in the HUVEC media. MDA-MB-231
(breast ER ve), PC-3 (prostate AR ve), MCF-7 (breast ERþve),
A2780 (ovarian ER ve) and LNCaP (prostate ARþve) cancer cells
were obtained from the American Type Culture Collection (LGC
Promochem, Teddington, UK) and maintained in Dulbecco’s
minimal essential medium containing phenol red, supplemented
with 10% fetal calf serum and antibiotics (Sigma, Poole, UK). All
cells were cultured at 371C under 5% CO2 in a humidified
incubator. HUVECs and dermal fibroblasts were used up to
passage 10.
To ascertain the IC50 values 5000–10000 cells, in their
appropriate growth medium, were added to each well of a 96-
well microtitre plate (Falcon; BD Biosciences, Cowley, UK). Plates
were incubated for 4–5h at 371C in a 5% CO2 humidified
atmosphere before addition of compounds at a final concentration
of 0.1nM to 10mM. All compounds were dissolved at 10
 2 M in
tetrahydrofuran (THF) with a final concentration of THF of 0.1%
or less. Cells were grown in the absence or presence of the
compounds for 5 days. At the end of this period, MTS (20ml per
well; Promega, Southampton, UK) was added and incubated for a
further 2h. Absorbance was recorded at 490nM with a 96-well plate
reader (FLUOSTAR; BMG, Aylesbury, UK).
Reversibility studies
Cells were plated at 60–70% confluency in T-25 flasks (Triple Red,
Thame, UK), and after 24h, they were treated with 0.5mM of the
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Figure 1 Structures: compound 1, 2-methoxyoestrone (2-MeOE1); compound 2, 2-methoxyoestradiol (2-MeOE2); compound 3, 2-methoxy-3-hydroxy-
17b-cyanomethyl-oestra-1,3,5(10)-triene (STX640); compound 4, 2-methoxy-3-O-sulphamoyl-17b-cyanomethyl-oestra-1,3,5(10)-triene (STX641); and
compound 5, 2-methoxyoestradiol-3,17-O,O-bis-sulphamate (STX140).
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srelevant compound. Control cells were treated with THF vehicle
only. After 3 days, the medium was aspirated and the cell
monolayers washed thoroughly. The number of cells in three flasks
for each treatment was determined by Coulter counting. Of the
remaining six flasks for each initial treatment, three were treated
with 0.5mM of the appropriate compound, and three with vehicle
alone. After a further 3 days, the remaining cells were counted
using a Coulter Counter.
Cell cycle analysis
Cells were plated at 60–70% confluency in T-25 flasks. After 24h,
they were treated with 0.5mM of compound for a further 24h.
Control cells were untreated or treated with THF vehicle only. To
harvest cells for flow cytometric DNA analysis, cells were washed
with PBS before being trypsinised (0.25% trypsin, 0.05% EDTA).
Media containing nonadherent cells were also collected and pooled
with the trypsinised cells. The cells and PBS washings were pelleted
by centrifugation at 1500r.p.m., washed twice with PBS, fixed in
cold 70% ethanol, treated with 100mgml
 1 RNase for 5min,
stained with 50mgml
 1 propidium iodide and analysed using a
flow cytometer (FACScan; Becton Dickinson, Cowley, UK).
Apoptosis analysis
Cells were plated at 60–70% confluency in T-25 flasks. After 24h,
they were treated with 0.5mM of compound. Control cells were
untreated or treated with THF vehicle only. To harvest cells for
flow cytometric analysis, cells were washed with PBS before being
trypsinised (0.25% trypsin, 0.05% EDTA). Any media containing
nonadherent cells were also collected and pooled with the
trypsinised cells. The cells and washings were pelleted by
centrifugation at 1500r.p.m., washed twice with PBS and re-
suspended in binding buffer (10mM HEPES/NaOH pH 7.4, 140mM
NaCl, 2.5mM CaCl2)a t1 10
6 cellsml
 1. Cells were then stained
with fluorescein-conjugated Annexin V (BD Biosciences) antibody
and propidium iodide (5mgml
 1) before flow cytometric analysis.
Apoptotic cells are defined as cells positive for Annexin V and
negative for propidium iodide.
Immunoblotting
T-25 flasks seeded at approximately 2.5 10
5 cells per flask in 5ml
of cell-specific media were incubated at 371C, 5% CO2 in a
humidified incubator. After 24h, the compounds were added and
the cells incubated for 24, 48 or 72h. Protein was prepared from
treated cells using RIPA lysis buffer (Sigma). Equal amounts of
protein were loaded in all wells. Proteins were separated by
electrophoresis through a 4–12% NuPAGE Bis-Tris gel (Invitrogen,
Paisley, UK) and subsequently transferred to Hybond-P membrane
(Amersham Biosciences, Little Chalfont, UK). Detection was
carried out using an anti-human cyclin B1 (sc-752) (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) primary antibody.
Tubulin polymerisation
The effects of test compounds (STX641, STX640 and STX140) on
in vitro polymerisation of purified bovine brain tubulin (Cytoskeleton,
Denver, CO, USA) were measured by turbidometry. Tubulin
(1mgml
 1) in MES buffer (0.1 M MES pH 6.5, 0.5mM MgCl2,1 M
monosodium glutamate and 1mM GTP) was incubated with or
without test compounds (10mM, 1% v/v ethanol) for 5min at 371C.
Tubulin assembly was stimulated by adding paclitaxel (10mM). The
change in the absorbance was continuously monitored at 350nm
for 15min at 371C. Because the amount of tubulin polymerised is
directly proportional to the area under the curve (AUC), it was
used to determine the extent of tubulin polymerisation by different
test compounds. The AUC of paclitaxel alone, with a maximal
extent of polymerisation, was set to 100% polymerisation.
Angiogenesis assay
The effect of the compounds on in vitro vessel formation was
assessed using an angiogenesis kit (TCS Cellworks). For this assay,
endothelial cells were cultured in a 24-well plate within a matrix of
human diploid fibroblasts of dermal origin in optimised medium
supplied by TCS Cellworks. The co-cultured cells were incubated
throughout the experiment at 371C under 5% CO2 in a humidified
incubator. On day 1, the culture medium was removed and
replaced with medium containing the compounds under investiga-
tion. On days 4, 7 and 9, the medium was replaced with fresh
medium containing the compounds. Each compound was tested
in triplicate. On day 11, the cells were washed (in PBS) and
70% ethanol (1ml) was added to each well for 30min to fix the
cells. After fixation, the cells were washed with blocking buffer
(1ml, PBSþ1% BSA) and stained for CD31 in accordance with the
manufacturer’s instructions (TCS Cellworks).
The extent of vessel formation was then quantified using a
variation of a previously described technique (Newman et al,
2004). Briefly, using a high-resolution transmissive scanner
(ScanMaker 9800; Microtek, Willich, Germany), each well was
scanned and saved as a TIF (Tagged Image Format) file in
Photoshop (Adobe, San Jose, CA, USA). The image was then
converted to a black and white image using the photocopy filter
in Photoshop (2 , 10 Detail, 25 Darkness) and saved as an
uncompressed TIF file. The files were transferred to the AngioSys
software (TCS Cellworks), all background and nontubule-like
structures were removed using the erode (1 ) and clean (100
pixels) functions, and the number of pixels representing vessels
was counted. This technique was validated (data not shown)
against the quantification techniques as described previously
(Newman et al, 2004).
Xenograft models
Female MF-1 nu/nu mice were injected subcutaneously (s.c.) in the
flank with 2 10
6 MDA-MB-231 cells. Twice weekly i.p. adminis-
tration of STX641 (40mgkg
 1) and STX640 (40mgkg
 1) was
compared with daily oral dosing of STX641 (40mgkg
 1). Dosing
was performed for 28 days after which animals were euthanised
and the tumours taken for histological and IHC studies.
Male MF-1 nu/nu mice were injected s.c. in the flank with
2 10
6 PC-3 cells. Daily oral dosing of STX140 (20mgkg
 1) was
compared with 2-MeOE2 100mgkg
 1 (daily, p.o.), bevacizumab
5mgkg
 1 (q3d 4, i.p.), taxotere 30mgkg
 1 (qwk 3, i.v.) and
vinorelbine 80mgkg
 1 (qwk 3, p.o.). At the end of the initial
28-day study, the decision was taken to extend the dosing in
STX140 arm for a further 32 days due to lack of toxicity and
promising efficacy being observed.
In both studies, animal weights and tumour measurements
were regularly taken using electronic callipers. Tumour volume
(V), in mm
3, was determined using the following equation:
length width
2/2 (l w
2/2).
Immunohistochemistry
Hematoxylin–eosin (H&E) staining and von Willebrand’s factor
IHC were performed on paraffin-embedded MDA-MB-231 tumour
sections cut at 6mm. After sectioning, rehydration and antigen
retrieval steps, von Willebrand’s factor antibody (1:800, Abcam,
Cambridge, UK) was applied to the section for 1h at RT, followed
by a goat polyclonal secondary antibody conjugated to FITC
(30min at RT). Sections were then mounted and viewed under a
light or fluorescence microscope.
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sStatistics
All in vitro experiments were carried out in triplicate, and data
presented are representative of one of three such experiments. All
errors shown are the mean±s.d. Student’s t-test was used to assess
the significance of the differences in cell proliferation in vitro. For
xenograft data, one-way ANOVA followed by a Bonferroni’s
multiple comparison test was performed to determine statistical
significance on most data sets. Where only two groups are
compared, a Student’s t-test was applied. All values are represented
as the mean±standard errors of the mean (s.e.m.). Data generated
in these studies were normally distributed as assessed by the
method of Kolmogorov and Smirnov. Statistics were calculated
using Prism 3 for Mac (GraphPad Software Inc., San Diego, CA,
USA).
RESULTS
Cell proliferation assays
The ability of STX641 and the corresponding nonsulphamoylated
compound STX640 to inhibit the proliferation of a panel of cell
lines was examined over a 4-day period (Table 1). The replacement
of the O-sulphamate group at the 17 position of STX140 with a
cyanomethyl group, to give STX641, increased in vitro potency by
two- to five-fold in the tumour cell lines tested. Removal of the
3-O-sulphamate group of STX641 to generate STX640 led to a
decrease in activity. The greatest decrease in potency was seen in
the PC-3 AR ve prostate cell line, where removal of the 3-O-
sulphamate moiety caused over an eightfold decrease in potency
(IC50 values; 50 vs 430nM). Inhibition of HUVEC proliferation was
used to assess the potential anti-angiogenic activity of these
compounds. All three compounds were potent inhibitors of
HUVEC proliferation with IC50 values of o50nM, thus indicating
that these compounds may be potent inhibitors of angiogenesis.
In contrast to their effects on cancer cells and HUVECs, human
adult dermal fibroblasts were relatively resistant to the anti-
proliferative effects of STX641, STX640 and STX140 with
IC50 values in excess of 5mM (data not shown).
Reversibility studies
To assess whether the growth inhibitory effects seen were
attributable to irreversible inhibition of cell proliferation or to
delayed cell death, PC-3 cells were exposed to 0.5mM STX641,
STX640 or STX140 for 3 days. The cells were then washed to
remove the compound and cultured for a further 3 days in the
absence of compound. In the prostate PC-3 cell line (Figure 2A),
there was an increase in cell number following the removal of
STX640 and STX140, but the rate of growth was still decreased
compared to untreated cells. However, STX641 continued to cause
a decline in the cell number, indicating that the cells were
irreversibly committed to cell death. Similar data have been
previously shown for STX140 in the hormone-independent breast
cancer cell line, MDA-MB-231 (Raobaikady et al, 2005).
Tubulin polymerisation
The inhibition of paclitaxel-stimulated tubulin polymerisation
in vitro is commonly observed with many microtubule destabilis-
ing agents, such as colchicine and the vinca alkaloids. Previously, it
has been shown that the sulphamoylated oestrone derivative,
2-methoxyoestrone-3-O-sulphamate, inhibited the paclitaxel-
stimulated tubulin polymerisation, as measured by changes in
turbidity (MacCarthy-Morrogh et al, 2000). In this study, both
STX641 and STX140 significantly inhibited paclitaxel-stimulated
tubulin polymerisation, with STX641 being the most potent
inhibitor (96.6% inhibition vs 87.8% inhibition, Figure 2B). The
Table 1 The effect of 2-substituted, C-17-modified oestrogens on cell
proliferation in a panel a cell lines (IC50 values in nM)
Cell line Origin STX641 STX640 STX140
a
PC-3 Prostate AR ve 50a,b 430c 270
MDA-MB-231
b Breast ER ve 80a,b 320NS 290
LNCaP Prostate AR+ve 60a,b 320NS 260
MCF-7 Breast ER+ve 150a,b 320c 250
A2780 Ovarian ER ve 90a,b 330NS 280
HUVEC Endothelial 30NS,b 30c 44
HUVEC¼human umbilical vein endothelial cell. Statistics: a, STX641 vs STX640
Po0.01; b, STX641 vs STX140 Po0.01; c, STX640 vs STX140 Po0.05; NS, not
significant.
aData presented for comparative purposes previously published by
Newman et al (2004) and Day et al (2003).
bData presented for comparative
purposes previously published by Utsumi et al (2005).
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Figure 2 STX641, STX640 and STX140 are irreversible inhibitors of
proliferation and disrupt microtubule dynamics. (A) PC-3 cells were
exposed to compounds as indicated (0.5mM) for 3 days, and cell numbers
were determined by Coulter counting. Cells were washed thoroughly to
remove compounds, and cell numbers determined after a further 3 days:
compound-free incubation (solid lines) or continued compound treatment
(dashed lines). Values are means of triplicate determinations; bars, s.d. (B)
In vitro tubulin assembly was measured by turbidity at 350nm. Tubulin was
incubated with or without test compounds (10mM) for 5min at 371C.
Tubulin assembly was stimulated by adding paclitaxel (10mM). The change
in the absorbance was continuously monitored at 350nm for 15min at
371C. The AUC was used to determine the extent of tubulin
polymerisation by different test compounds. The AUC of paclitaxel alone,
with a maximal extent of polymerisation, was set to 100% polymerisation.
The AUC for the test compounds was STX640, 63%; STX641, 3.4%; and
STX140, 12.2%.
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snonsulphamoylated derivative, STX640, had some inhibitory
activity (37% inhibition), in contrast to 2-MeOE2, which was
previously shown to be inactive in this assay (MacCarthy-Morrogh
et al, 2000). The vehicle alone, ethanol, had no effect on the
paclitaxel-stimulated polymerisation of tubulin (data not shown).
Cell cycle analysis
It has been demonstrated that sulphamoylated derivatives of 2-
MeOE1 and 2-MeOE2 are able to induce cell cycle arrest in MCF-7,
ZR-75-1, CA51 and CAMA1 cells (MacCarthy-Morrogh et al, 2000).
In this study, we examined the effect of C-17 modifications on cell
cycle arrest in the hormone-independent PC-3 prostate cell line. In
untreated PC-3 cells, approximately 60% of the cells are in G1 and
22% are in G2/M (Figure 3A). After treatment with 0.5mM STX641
for 24h, 70% of PC-3 cells entered G2/M arrest, with only 6% in
G1, which is almost the same distribution observed following
0.5mM STX140 treatment of PC-3 cells for 24h (Figure 3A). The
nonsulphamoylated compound, STX640 (0.5mM), also potently
induced cell cycle arrest with 71% of PC-3 cells being in G2/M after
24h and 6% in G1.
Apoptosis
Cells exiting cell cycle arrest either continue through the cell cycle
or undergo apoptosis. In this study, the capacity of STX641,
STX640 and STX140 to induce apoptosis in the hormone-
independent PC-3 prostate cell line was examined by looking at
Annexin V flip out. Apoptosing cells are detected in the M2 region
of the histogram in Figure 3B. All compounds induced significant
(Po0.001) apoptosis after 72h with respect to vehicle-treated
control in PC-3 cells. Quantification of the histograms revealed no
significant difference between the compounds. The data presented
here compliment that of Raobaikady et al (2005), which
demonstrated that STX140 induces apoptosis in the hormone-
independent breast cancer line, MDA-MB-231.
The timing of the cell cycle arrest and subsequent apoptosis was
further confirmed by immunoblotting for the cell cycle protein
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Figure 3 STX641, STX640 and STX140 cause cell cycle and subsequent apoptosis in PC-3 cells. (A) PC-3 cells were treated with 0.5mM compound for
24h, before being fixed and stained with propidium iodide and analysed using a flow cytometer and CellQuest Pro software. The plots represent one of at
least three representative experiments. (B) To identify cells undergoing apoptosis, PC-3 cells were treated with compounds (0.5mM) as indicated for 72h.
The cells were then harvested and stained with fluorescein-conjugated Annexin V antibody and propidium iodide before analysis using flow cytometer and
CellQuest Pro software. The cells undergoing apoptosis are in M2 region of the histogram. The percentage of cells undergoing apoptosis is control, 4%;
STX640, 16%; STX641, 16%; and STX140, 14%. The plots represent one of at least three representative experiments. (C) Immunoblot showing induction of
cyclin B1. PC-3 cells were treated with compound (0.5mM) for 24h, and total cell protein extracted and immunoblotted for cyclin B1.
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scyclin B1 in PC-3 cells. The induction of cyclin B1 by all three
compounds coincided with the observed cell cycle arrest
(Figure 3C). Once cyclin B1 levels start to decrease (48h onwards),
the cells undergo apoptosis (Figure 3B).
Inhibition of in vitro angiogenesis
As these compounds are potent inhibitors of endothelial cell
proliferation (Table 1 and Newman et al, 2004), their ability to
inhibit in vitro angiogenesis was assessed. In this study, a
co-culture model was used in which endothelial cells are co-
cultured with fibroblasts in a specially formulated medium. The
pro-angiogenic factor VEGF (2ngml
 1) was used to further
stimulate vessel formation in this assay, and the compounds’
capacity to inhibit the VEGF-stimulated angiogenesis was assessed.
The representative high-resolution scans of the wells clearly
show that both 100nM STX641 and STX640 inhibit VEGF-
stimulated vessel formation (Figure 4A). Quantification of the
scans, using a previously validated method (Newman et al, 2004),
shows that STX641 at both 20 and 40nM completely blocked all
tubule formation (Figure 4B). In contrast, STX140 does not
completely inhibit at 20nM (data not shown), although it does
give complete inhibition at 100nM (Newman et al, 2004). The
nonsulphamoylated compound STX640 was not active at either 20
or 40nM (data not shown), but did inhibit tubule formation by
92% ±2 at 100nM (Figure 4B).
Xenograft studies
The hormone-independent MDA-MB-231 breast xenograft model
is a very robust and widely used model for the assessment of
microtubule disruptors. Therefore, this model was initially used
to assess the efficacy of STX641 and STX640 in vivo. Tumours in
untreated mice increased by over 2000% in size (2215%±565
s.e.m.) over the study period; in contrast, tumours in mice treated
with STX640 (40mgkg
 1 i.p.; twice weekly) or STX641 (40mgkg
 1
i.p.; twice weekly) were significantly smaller (Po0.001) and had
only increased in size by 550% ±111 s.e. and 424%±90 s.e.,
respectively. Daily oral dosing with STX641 (40mgkg
 1 p.o.; daily)
was equally as efficacious as the twice weekly i.p. dosing regime:
tumours increased in size by 803% ±101 s.e. (Figure 5A). No
toxicity was associated with any regime (data not shown).
To assess the in vivo anti-angiogenic activity of these
compounds 6mm sections of paraffin-embedded tumour were cut
and stained for the endothelial-specific cell marker, von Will-
ebrand’s factor. STX641, both p.o. and i.p., significantly reduced
the number of endothelial cells in tumour sections from treated
mice relative to those in tumour sections from untreated mice
(Figure 5B). H&E staining (Figure 5C) revealed three distinct
layers, a necrotic tumour centre (N) surrounded by a healthy,
viable rim (V) with a further layer of dermis (D). The tumours
taken from the vehicle-treated animals generally demonstrated a
larger tumour rim compared to the STX641- and STX640-treated
mice.
Despite its greater efficacy in vitro (Table 1), STX641 was not as
potent as STX140 in vivo. STX641 was efficacious in the MDA-
MB-231 xenograft model at 40mgkg
 1 p.o. (Figure 5A), whereas
STX140 showed significantly greater efficacy at 20mgkg
 1 p.o. in a
hormone-independent xenograft model (Ireson et al, 2004). On the
basis of these observations, STX140 was selected for evaluation in
the hormone-independent prostate PC-3 cell line against a panel
of preclinical and clinical comparator compounds (Figure 6A).
STX140 (20mgkg
 1 p.o.; daily) caused significant regression
(Po0.05) after 28 days relative to the starting volumes of the
tumours. No other compound caused significant tumour regres-
sion at day 28. Vinorelbine (80mgkg
 1 p.o.; qwk 3) prevented
tumour growth, however significant weight loss was observed
(Figure 6A) and two animals died during the study, indicative of
significant toxicity. Docetaxel (30mgkg
 1 i.v.; qwk 3) signifi-
cantly (Po0.001) slowed tumour growth, but tumour size still
increased four-fold with docetaxel dosing. Both bevacizumab
(5mgkg
 1 i.p.; q3d 4) and 2-MeOE2 (100mgkg
 1 p.o.; daily)
had no significant effect on tumour growth relative to vehicle (10%
THF/90% propylene glycol (PG)).
Extended (28 daysþ32 days¼60 days) daily dosing with
STX140 (20mgkg
 1 p.o.) led to 5/8 tumours regressing and 3/8
not increasing in size. After the cessation of dosing on day 60,
the growth of 5/8 tumours was followed for a further 67 days
(Figure 6B). Of these tumours, 2/5 disappeared by day 88 and were
still undetectable at the end of study (D), 1/5 progressed slowly and
had only increased in volume by threefold at day 127 relative to
d a y0( r). The remaining two tumours grew rapidly and the
animals were taken off study on day 107 (B). No significant
weight loss was seen during the 60-day dosing schedule or the
67-day follow-up period (Figure 6B, inset). All the untreated
tumours (J) grew rapidly, and the animals were all taken off
study by day 50 as the tumours had exceeded 2000mm
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Figure 4 Vessel formation in an in vitro model of angiogenesis. (A)
Representative high-resolution scans showing the effects of the indicated
compounds on vessel formation by co-cultures of endothelial cells and
fibroblasts. Cells were exposed to compounds for 11 days, and the tubules
were stained using an antibody for CD31. (B) Co-cultures of endothelial
cells and fibroblasts were exposed to compounds for 11 days. The tubules
were stained using an antibody for CD31 and quantified by high-resolution
scanning and subsequent image processing to quantify the number of pixels
per well representing tubules. Values are means of triplicate determinations:
bars; s.d. ***
aPo0.001 vs control and ***
bPo0.001 vs VEGF.
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sDISCUSSION
Recent studies by Liu et al (2005) and our group (Newman et al,
2006) have highlighted the limitations of 2-MeOE2 as a therapeutic
agent due to its potential for metabolism and subsequent
inactivation by 17b-HSD type 2 at the C-17 position in the
D-ring. This suggested a need for protective modification of
2-MeOE2 and other similar compounds at this position. Therefore,
the effects of further C-17 modifications to the A-ring-modified
sulphamoylated compounds previously investigated by our group
(MacCarthy-Morrogh et al, 2000), and, in addition, the effects of
C-17 modification on the activity of a related nonsulphamoylated
compound have been explored.
In vitro studies have shown STX140 to be a potent inhibitor of
proliferation in a wide range of tumour cell lines, with IC50 values
approximately 10-fold less than 2-MeOE2 (Day et al, 2003;
Newman et al, 2004). In this study, the replacement of the 17-O-
sulphamate of STX140 with a cyanomethyl group signifi-
cantly enhances the anti-proliferative activity. Furthermore, the
nonsulphamoylated C-17 cyanomethyl compound, STX640, was
approximately 10 times more potent than 2-MeOE2. These results
indicate that a C-17 cyanomethyl group is able to impart anti-
proliferative activity on this class of compounds, even in the
absence of a 3-O-sulphamate group. All three compounds caused
irreversible inhibition of cell proliferation, with only minimal
proliferation in STX140- and STX640-treated PC-3 cells after
compound removal. Thus, further demonstrating the importance
of the C-17 cyanomethyl substitution, as previous studies
(MacCarthy-Morrogh et al, 2000; Day et al, 2003; Raobaikady
et al, 2005) have shown the nonsulphamoylated 2-MeOE2 to be a
reversible inhibitor of cell proliferation.
To further characterise the C-17 cyanomethyl derivatives, their
effects on the cell cycle were assessed and compared with those of
STX140 in the PC-3 cells. All compounds caused G2/M cell cycle
arrest and subsequent apoptosis, there was no significant
difference in efficacy between the compounds. The potency of
STX640 in this assay again emphasises the value of adding a C-17
cyanomethyl group to this class of compound. The proliferation,
cell cycle and apoptosis data were further supported by the
improved activity of STX641 vs STX140 and STX640 vs 2-MeOE2
in the inhibition of paclitaxel-stimulated tubulin polymerisation.
This highlights the potential tubulin interaction role of the C-17
cyanomethyl and possibly explains the better efficacy of
C-17 cyanomethyl compounds.
2-MeOE2, STX641, STX640 and STX140 inhibit the proliferation
of HUVECs, and this is an indicator of potential anti-angiogenic
activity. Using a previously described (Newman et al, 2004) in vitro
co-culture model of angiogenesis, the anti-angiogenic potential of
STX641 and STX640 was assessed. Both compounds were potent
inhibitors of VEGF-stimulated angiogenesis in this model, with
STX641 being the most potent compound. In this same assay,
100nM 2-MeOE2 had no effect (Newman et al, 2004); in contrast,
the nonsulphamoylated STX640 reduced angiogenesis by 90%.
The mechanisms by which 2-MeOE2 and related sulphamoylated
derivatives inhibit angiogenesis have yet to be fully resolved. One
likely explanation arises from the observations that both
2-MeOE2 and related sulphamoylated derivatives cause G2/M
arrest in endothelial cells (Lakhani et al, 2003; Newman et al,
2004), inhibit the proliferation of endothelial cells, and the
sulphamate derivatives have been shown to induce Bcl-2
phosphorylation and apoptosis in endothelial cells (Newman
et al, 2004). Thus, it seems likely that in a growing tumour, the
endothelial cells will be rapidly dividing to meet the tumour’s
demand for angiogenesis, and that this class of compound may act
as a classic microtubule disruptor, inducing apoptosis in rapidly
dividing cells whether they are of tumour or endothelial origin.
This concept is currently being evaluated for many ‘traditional’
chemotherapeutic compounds, with regular, low (metronomic)
dosing being used in an effort to maximise the anti-angiogenic
action and maintain the anti-tumour activity (Vacca et al, 1999;
Hanahan et al, 2000; Bertolini et al, 2003).
The potential anti-angiogenic activity of STX641 identified in
vitro was confirmed by the reduction in staining for von
Willebrand’s factor, an endothelial cell-specific marker, observed
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Figure 5 MDA-MB-231 xenograft studies. (A) STX641 (40mgkg
 1, p.o. and i.p.) and STX640 (40mgkg
 1 i.p.) inhibited MDA-MB-231 xenograft
tumour growth in vivo. Data represent mean±s.e.m. (n¼5). *Po0.05 when compared to vehicle control (10% THF/90% PG; p.o.). (B) The effect of
compounds on tumour histology and vasculature. Von Willebrand’s staining of blood vessels indicated that the vehicle tumours were not greatly vascularised
(A). However, administration of STX641 via either p.o. or i.p. caused a decrease in blood vessels. STX640 did not affect the vasculature of the tumours.
Magnification  200. In H&E stained tumour sections (B), three distinct areas were observed. A necrotic centre (N) surrounded by a section of viable
tumour rim (V) with an outer dermis layer (D). The tumours of the vehicle-treated animals had a generally large tumour rim. This was smaller in the
compound-treated groups, where STX641 caused a smaller rim than STX640. Magnification  100.
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sin vivo. Surprisingly, the significantly improved efficacy of STX641
in comparison to STX140 in vitro did not translate to significant
improvements in vivo; in fact, comparison with STX641 shows
STX140 to be more potent at inhibiting both tumour growth
(Ireson et al, 2004) and in vivo angiogenesis (Chander et al, 2007).
The observation that twice weekly i.p. administration of STX641
was equipotent to daily p.o. administration at the same dose
(40mgkg
 1) strongly indicates that STX641 may not be as readily
orally bioavailable as STX140 with the formulation used. For these
reasons, STX140 was selected for further in vivo studies in the
hormone-independent PC-3 prostate xenograft model. To fully
assess the potential of STX641, further formulation and PK studies
need to be undertaken. To evaluate STX140, it was tested against a
range of clinically relevant drugs. Both STX140 (20mgkg
 1 p.o.)
and vinorelbine (80mgkg
 1 p.o.) completely inhibited tumour
growth over a 28-day period. However, in contrast to vinorelbine,
STX140 did not cause any significant weight loss. Docetaxel,
which is commonly used to treat hormone-independent prostate
cancer, only slowed the rate of tumour growth by about 50%.
This, taken in conjunction with its associated toxicity and lack of
oral bioavailability in the clinic, indicates that there is significant
room for improvement in the treatment of advanced prostate
cancer.
Bevacizumab inhibits VEGF and prevents its binding to the
VEGFR2 and stimulating angiogenesis. In this study, bevacizumab
had no significant effect on tumour growth. The role of VEGF in
sustaining the growth of PC-3 xenografts is difficult to ascertain as
Takei et al (2004) showed siRNA against VEGF could reduce
xenograft growth, but Dev et al (2004) showed that PC-3 cells
expressed little VEGF and were not sensitive to a VEGFR2
inhibitor. The poor efficacy of 2-MeOE2 in vivo was further
highlighted by its lack of activity in the PC-3 model, despite daily
dosing at 100mgkg
 1 p.o. Data generated from this study strongly
favour STX140 as a potential clinical candidate for hormone-
independent prostate cancer. Further studies could be undertaken
using more sophisticated in vivo models, such as orthotopic or
metastatic prostate models to expand upon these results. The use
of STX140 was further supported by extended dosing studies, in
which STX140 could be administered daily (20mgkg
 1 p.o.) for 60
days with no toxicity being observed. This prolonged dosing
schedule produced remarkable results with complete or partial
responses seen in 8/8 tumours. Furthermore, no tumours could be
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Figure 6 PC-3 xenograft studies. (A) STX140 (20mgkg
 1 p.o.; daily) was tested against a range of clinical and preclinical compounds in the hormone-
independent PC-3 xenograft model: vehicle (10% THF/90% PG; p.o.), 2-MeOE2 (100mgkg
 1 p.o.; daily), bevacizumab (5mgkg
 1 i.p.; q3d 3), docetaxel
(i.v.; qwk 3) and vinorelbine (80mgkg
 1 p.o.; qwk 3). Data represent mean±s.e.m. (n¼8). *Po0.05 when compared to tumour starting volume.
Animal weights taken over the 28-day study (inset). (B) Individual tumour data for the vehicle (10% THF/90% PG) and STX140 (20mgkg
 1 p.o.; daily) arms
for the 60-day dosing schedule and the subsequent 67-day follow-up. When tumours exceeded approximately 2000mm
3, the animals were euthanised.
Animal weights taken over the 127-day study (inset).
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sdetected in the 2/8 complete responses 67 days after the cessation
of dosing.
This study demonstrates for the first time that addition of a C-17
cyanomethyl group significantly enhances the in vitro and in vivo
efficacy of 2-MeOE2-like compounds. The cyanomethyl-substi-
tuted compounds STX640 and STX641 disrupt microtubule
dynamics leading to apoptosis, and both are potent (nM range)
inhibitors of in vitro angiogenesis. In vivo, in the hormone-
independent MDA-MB-231 breast xenograft model, both com-
pounds significantly inhibit tumour growth. However, in vivo,
neither compound is as potent as STX140, which was shown to be
superior to a range of clinical and developmental compounds,
including docetaxel and bevacizumab, in the PC-3 hormone-
independent xenograft model. Finally, data presented in this study
suggest that STX140 may allow for regular, oral, prolonged dosing
regimes with minimal toxicity and without the need to compro-
mise the dose used. Thus, STX140 could be regarded as a new
generation of oral microtubule disruptor, which has direct anti-
tumour activity and reduces tumour vasculature at one optimal
dose. These properties suggest that this compound could be
efficacious in both hormone-independent prostate and breast
cancer. STX140 is envisaged to enter the clinic in 2008.
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